Prevalence and prognostic impact of BRAF V600E mutation and CDKN2A deletion in pediatric high-grade glioma
Neither BRAF V600E mutation nor CDKN2A deletion status significantly impacted this cohort's progression-free survival (PFS). Patients with these mutations now have access to new targeted BRAF V600E inhibitors, which may improve their outcomes.
Authors
- Amal Mosaab (ORCID: https://orcid.org/0000-0001-7786-063X)
- Hanafy Hafez (ORCID: https://orcid.org/0000-0003-1093-933X)
- Sherine Salem (ORCID: https://orcid.org/0000-0002-9799-9687)
- Mohamed El‐Beltagy (ORCID: https://orcid.org/0000-0003-3856-4015)
- Alaa Elhaddad (ORCID: https://orcid.org/0000-0003-3538-5038)
- Ahmed Elhemaly (ORCID: https://orcid.org/0000-0003-3699-5348)
- Eslam Maher (ORCID: https://orcid.org/0000-0001-5428-1555)
- Mohamed S. Zaghloul (ORCID: https://orcid.org/0000-0002-1999-6528)
- Mark W. Kieran (ORCID: https://orcid.org/0000-0003-2184-7692)
- S. Karim
- Mohamed Kamal (ORCID: https://orcid.org/0000-0001-8663-8846)
- Iman M. Naguib
- Hala Taha (ORCID: https://orcid.org/0000-0001-8068-9431)
- Amal Refaat
Institutions
- Cairo University (EG)
- Children Cancer Hospital (EG)
- Imperial College London (GB)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-08-08
- DOI
- https://doi.org/10.3389/fonc.2025.1537268
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00